Revisions to National Drug Schedules effective January 20, 2020.
The National Association of Pharmacy Regulatory Authorities (NAPRA) has announced the National Drug Schedules have been revised to reflect two changes regarding fluticasone propionate nasal spray:
- Fluticasone propionate, when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 18 years of age and older, in package sizes containing no more than 360 metered sprays, has been granted Schedule III status.
- Fluticasone propionate, when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 18 years of age and older, in package sizes containing more than 360 metered sprays, has been granted Schedule II status.
These changes were originally recommended by the National Drug Scheduling Advisory Committee (NDSAC) on December 9, 2019. NAPRA did not receive any comments on the proposed changes during a 30-day review period. NAPRA’s Board of Directors gave final approval to the changes, effective January 20, 2020.
For more information, refer to the National Drug Schedules.
